Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor. The […]

On International Day of Women in Science. #Kognitic would like to celebrate the great strides which women are making in science. At our company women account […]

Today is World Cancer Day, a day to reflect upon what strides we have been making toward helping the millions of patients battling cancer and focus […]

The National Institute for Health and Care Excellence has recommended #Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritonealcancer in adults with […]

#BeiGene presented its upcoming milestones for their #pipeline today at #JPM20, including projected approvals and submissions for #tislelizumab, #zanubrutinib, and #pamiparib. Why wait until the conference […]

#Roche presented its late stage pipeline today at #JPM20, with #tecentriq heading up #oncology with six anticipated indications, including expansions in #HCC, #TNBC, #bladdercancer, #melanoma, #ovariancancer, […]

A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developing the drug under the code […]

#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote […]

The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million Americans living with a history of cancer last year, […]